What Is iPSC Medium and Why Is It Important?

iPSC medium is the nutrient solution used to grow and maintain induced pluripotent stem cells, the reprogrammed adult cells that behave like embryonic stem cells. It supplies the precise mix of growth factors, signaling molecules, vitamins, and energy substrates that keep these cells multiplying without losing their ability to become any cell type in the body. Getting the medium wrong, even slightly, can cause cells to spontaneously turn into unwanted tissue, stop dividing, or accumulate genetic damage. That makes the medium one of the most consequential variables in stem cell science, affecting everything from basic lab research to the feasibility of future cell therapies.

What iPSC Medium Actually Contains

At its core, iPSC medium is a liquid formulation designed to do two things simultaneously: fuel rapid cell division and suppress differentiation. The base is typically a standard cell-culture nutrient broth containing amino acids, glucose, salts, and vitamins. What makes iPSC medium distinctive is the cocktail of signaling proteins and small molecules layered on top of that base. Two growth factors dominate most formulations: basic fibroblast growth factor (bFGF, also called FGF2) and transforming growth factor beta (TGF-β). Together, these molecules activate internal signaling pathways that keep the cells in a self-renewing, pluripotent state.

TGF-β signaling plays a complex and somewhat contradictory role. Depending on the stage of reprogramming and the cellular context, it can either block or promote the maintenance of pluripotency, and its interaction with bFGF signaling is part of what suppresses spontaneous differentiation in established iPSC cultures.¹ Beyond growth factors, modern iPSC media include insulin (to support metabolic activity), transferrin (for iron delivery), selenium (an antioxidant cofactor), and sometimes lipid supplements. The goal is to create an environment so precisely tuned that the cells behave as though they are sitting inside a very early-stage embryo, indefinitely.

Why bFGF Is Both Essential and Frustrating

bFGF is arguably the single most important ingredient in standard iPSC medium, and also one of the most troublesome. Under normal cell-culture conditions (around 37°C), native bFGF has a half-life of roughly eight hours. It degrades quickly, meaning that the concentration in the dish plummets between feedings.² In practice, this forces labs to change the medium every day, a labor-intensive routine that drives up costs and introduces variability.

Researchers have tackled this by engineering thermostable versions of bFGF (TS-bFGF). One approach uses an engineered disulfide bond that raises the protein’s melting temperature from about 58°C to 65°C. The resulting protein stays active at room temperature for up to twelve months, a dramatic improvement over the wild-type version.² In cell-culture conditions, native bFGF drops by about 95% after 48 hours even with added heparin (a stabilizer), while TS-bFGF retains enough activity after two days to match the levels you’d see 24 hours after adding fresh native bFGF with daily medium changes. Because TS-bFGF does not need heparin for stability, heparin, which is typically derived from pigs, can be dropped from the formulation entirely, making the medium both simpler and free of animal-derived components.³

The practical payoff is significant: switching from daily to every-other-day feeding cuts labor, reduces the chance of contamination each time you open a dish, and lowers the total amount of growth factor consumed. For labs running dozens of cell lines in parallel, that translates into real savings in time and money.

From Feeder Cells to Defined, Xeno-Free Formulations

Early iPSC culture relied on feeder cells, typically a layer of irradiated mouse embryonic fibroblasts spread across the bottom of the dish. These feeder cells secreted a poorly characterized mix of growth factors and extracellular matrix proteins that kept iPSCs happy. One early demonstration showed that even a bovine granulosa cell line could supply a conditioned medium capable of maintaining iPSC self-renewal and pluripotency, with cells retaining their ability to form all three embryonic germ layers in laboratory tests and in animal models.⁴ The approach worked, but it introduced animal-derived and poorly defined biological material, a problem for reproducibility and an outright barrier for any clinical application.

The field has since moved decisively toward chemically defined, xeno-free media. “Chemically defined” means every ingredient is known at a precise concentration, with no mysterious soup of secreted factors. “Xeno-free” means no animal-derived components, which matters both for regulatory approval and for eliminating the risk of transmitting animal pathogens to human cells. A pivotal step was the development of strategies to replace feeder cell layers with purified extracellular matrix proteins, allowing iPSCs to grow on coated surfaces in fully defined media.⁵

Today, formulations like Essential 8 (E8) contain just eight components: a base medium plus bFGF, TGF-β, insulin, transferrin, selenium, L-ascorbic acid, and NaHCO₃. When paired with a defined xeno-free matrix such as vitronectin, E8 supports robust iPSC expansion under scalable conditions, achieving cell densities in the range of 1.4 million cells per milliliter in stirred microcarrier systems after ten days of culture.⁶ That kind of reproducibility was unimaginable in the feeder-cell era.

The Surface Beneath the Cells Matters Too

Medium chemistry is only half the story. iPSCs also need physical anchorage to a surface, and the proteins coating that surface send signals through the cell membrane that help maintain pluripotency. The key players are integrins, receptors on the cell surface that latch onto extracellular matrix proteins. Specific integrins, including α6β1 and αvβ5, engage matrix proteins like laminin-511/521 and vitronectin. These interactions trigger downstream signaling cascades that sustain the expression of core pluripotency factors such as OCT4, NANOG, and SOX2.⁷

Research comparing iPSCs grown on Matrigel (a mouse-derived matrix extract) versus vitronectin (a human protein) has shown that different integrins take the lead depending on the surface. On Matrigel, β1 integrins are required for both adhesion and proliferation. On vitronectin, αvβ5 handles initial cell attachment, but blocking both αvβ5 and β1 is needed to significantly reduce proliferation.⁸ This means the choice of coating protein isn’t cosmetic. It changes which signaling pathways the cells activate, and those pathways feed back into whether the cells stay pluripotent or start drifting toward differentiation.

For scalable manufacturing, researchers have developed xeno-free microcarriers, tiny beads that cells attach to while floating in a stirred bioreactor. Simply coating polystyrene beads with vitronectin alone was not enough to support iPSC growth in stirred suspension. Adding recombinant human serum albumin and treating the beads with UV irradiation solved the problem, enabling cells to expand more than 20-fold per passage without losing pluripotency.⁹

ROCK Inhibitors and the Passaging Problem

iPSCs are notoriously fragile when you try to split them. During passaging, cells are separated from their neighbors and from the surface, then transferred to a new dish. This process triggers a wave of cell death, partly because isolated human pluripotent stem cells are prone to a form of programmed death called anoikis, which kicks in when cells lose their normal cell-to-cell contacts.

A small molecule called Y-27632, which inhibits an enzyme known as ROCK, has become a near-universal additive during passaging. The mechanism appears to involve promoting cell-cell interactions, allowing the dissociated cells to quickly form small aggregates rather than dying as isolated singles.¹⁰ ROCK inhibitor is typically added only at seeding and removed from the medium the next day, making it a temporary rescue agent rather than a permanent component. In bioreactor protocols, for instance, cells are seeded into the vessel with ROCK inhibitor on day zero, and the inhibitor is washed out at the first medium change 24 hours later.¹¹

Naive Versus Primed Pluripotency

Not all pluripotent states are the same, and the medium determines which state the cells settle into. Standard iPSC media like E8 and mTeSR1 maintain cells in a “primed” state, resembling the post-implantation epiblast of a human embryo. But researchers have developed alternative media that push cells into a “naive” state, which resembles the pre-implantation epiblast and has somewhat different gene expression and functional properties.¹²

The media recipes for naive cells look quite different. They typically include inhibitors of MEK and GSK3β (the so-called “2i” cocktail), leukemia inhibitory factor (LIF), and sometimes additional kinase inhibitors. One study comparing two naive media found that cells in T2iLGö medium (which includes a PKC inhibitor) clustered with epiblast cells in gene-expression analyses, while cells in RSeT medium (which includes FGF2, TGF-β1, and inhibitors of JNK and p38) sat partway between the primed and naive states.¹³ The medium composition, in other words, isn’t just feeding the cells. It is actively specifying what developmental stage they occupy.

Naive iPSCs have attracted interest because they may offer advantages for certain applications, including generating chimeric models for drug testing and studying very early human development. But they are harder to maintain, more metabolically demanding, and less well standardized. Naive cells exhibit higher glycolytic activity and rely more heavily on MYC-driven transcriptional programs compared to primed cells.¹⁴ When glycolysis is reduced, naive cells lose their self-renewal capacity, while primed cells grown on feeder layers are largely unaffected. This metabolic difference adds another dimension to the medium design challenge: the energy substrates and metabolic environment must match the pluripotency state you want to maintain.

Protecting Genomic Integrity During Reprogramming

One underappreciated function of medium composition is its influence on the genetic stability of iPSCs. The reprogramming process itself subjects cells to replication stress, where the DNA copying machinery encounters obstacles and can generate breaks in the genome. If those breaks accumulate, the resulting iPSC line may carry mutations that compromise its safety or utility.

Researchers have found that supplementing the medium with nucleosides, the building blocks of DNA, during reprogramming can reduce this stress. Nucleoside supplementation progressively lowered markers of DNA damage during reprogramming, and this effect held regardless of whether the reprogramming cocktail included the oncogene cMYC. The nucleosides rescued the reduced speed of DNA replication forks caused by reprogramming factors, essentially giving the cell’s copying machinery the raw materials it needed to keep up with the accelerated division rate.¹⁵ This is a clear case where a simple medium tweak, adding extra nucleosides, has outsized consequences for the quality of the cells you end up with.

Scaling Up for Therapeutic Manufacturing

Growing a few million iPSCs for a research experiment is one thing. Producing the billions of cells needed for a single dose of a cell therapy is a fundamentally different engineering problem, and the medium is at the center of it. Suspension culture in bioreactors, where iPSCs grow as free-floating aggregates rather than on flat dishes, has emerged as the most promising path to clinical-scale production.

In one approach, iPSCs are seeded into small vertical-wheel bioreactors in about 55 mL of medium with ROCK inhibitor, then topped up the next day. By day five, the clusters are harvested or dissociated for further expansion. Suspension culture has been shown to improve not just cell yields but also the quality of the pluripotency phenotype compared to conventional flat-dish culture.¹¹ Other groups have pushed further, using controlled low oxygen levels and perfusion feeding to reach cell densities of 4.7 million cells per milliliter, with total expansion factors of about 19-fold per run.¹⁶

These numbers matter enormously for the economics of cell therapy. A cardiac patch might require hundreds of millions of cardiomyocytes; a retinal treatment might need far fewer but with extreme purity. In every case, the medium must sustain exponential growth while keeping the cells in a state from which they can be reliably steered toward the desired tissue type.

The Cost Problem

iPSC medium is expensive, and the expense is concentrated in a few key ingredients. In the Essential 8 formulation, nearly 98% of the medium cost comes from just two recombinant proteins: FGF-2 and TGF-β. For other serum-free media, albumin, FGF-2, and insulin collectively account for around 60% of the total cost.¹⁷ At manufacturing scale, medium accounts for at least half of the variable operating costs.

This cost structure has real consequences. It limits how many labs can afford to work with iPSCs, it constrains the size of experiments, and it poses a serious barrier to making iPSC-derived therapies affordable for patients. The thermostable bFGF variants discussed earlier are one part of the solution, because they reduce the total amount of growth factor consumed per cell produced. Other strategies under active development include producing growth factors in cheaper expression systems such as plants or yeast, engineering cells to produce their own growth factors (autocrine engineering), and identifying small-molecule substitutes that mimic the effects of expensive recombinant proteins.

From Research-Grade to Clinical-Grade Medium

Using iPSC-derived cells in patients requires medium that meets Good Manufacturing Practice (GMP) standards, a regulatory framework that demands full traceability of every component, documented consistency between batches, and freedom from animal-derived materials. Few iPSC lines have been produced under GMP-compliant conditions, and establishing the infrastructure to do so is a significant undertaking involving validated in-house platforms for every step from reprogramming through expansion.¹⁸

Quality control for clinical-grade iPSCs goes beyond just confirming that cells express the right surface markers. A recent reassessment of marker genes in human iPSCs highlighted the need for more rigorous quality-control panels, using directed differentiation into all three germ layers with standardized commercial kits to verify that cells retain full developmental potential.¹⁹ The medium used during this quality-control differentiation step is itself tightly specified, with precise seeding densities and matrix coatings for each lineage. Even small deviations in the culture environment during testing could give misleading results about whether a cell line is truly fit for therapeutic use.

Why Medium Variability Haunts Reproducibility

One of the persistent frustrations in iPSC research is that the same cell line can behave differently in different labs, or even in the same lab from week to week. Medium variability is a major driver of this irreproducibility. Lot-to-lot differences in recombinant proteins, degradation of bFGF between feedings, subtle shifts in osmolality or pH during storage, and inconsistent matrix coating can all push cells toward slightly different states. The cells may still look pluripotent by standard marker staining but perform differently when you try to differentiate them into a specific tissue.

This is why the trend toward fully defined, minimal formulations like E8 has been so consequential. Fewer components means fewer sources of variation. Recombinant substrates like truncated vitronectin (VTN-N) and laminin-511 E8 fragments, paired with defined media, now support robust iPSC expansion under conditions compatible with GMP manufacturing.⁷ The combination of fewer ingredients, engineered protein stability, and standardized surfaces is gradually closing the reproducibility gap, though it has not disappeared entirely. Every time a lab substitutes one brand of vitronectin for another, or thaws a new lot of medium, there is a chance that the cells will respond differently. Managing that variability is as much a part of iPSC science as the biology itself.

1
PubMed Central. TGF-β signaling pathway in induced pluripotent stem cells reprogramming
2
PubMed Central. Thermostable Human Basic Fibroblast Growth Factor (TS-bFGF) Engineered with a Disulfide Bond Demonstrates Superior Culture Outcomes in Human Pluripotent Stem Cell
3
PLOS ONE. A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells
4
PubMed. Induced pluripotent stem cells’ self-renewal and pluripotency is maintained by a bovine granulosa cell line-conditioned medium
5
Recent Advances in iPSC Technology. Strategies for iPSC expansion: from feeder cells to laminin
6
PubMed Central. Defined Essential 8™ Medium and Vitronectin Efficiently Support Scalable Xeno-Free Expansion of Human Induced Pluripotent Stem Cells in Stirred Microcarrier Culture Systems
7
PubMed. Integrin Signaling and ECM Proteins in hPSC Maintenance and Differentiation
8
Stem Cells and Development. Roles of integrins in human induced pluripotent stem cell growth on Matrigel and vitronectin
9
ACS Biomaterials Science & Engineering. Engineering Xeno-Free Microcarriers with Recombinant Vitronectin, Albumin and UV Irradiation for Human Pluripotent Stem Cell Bioprocessing
10
PLoS ONE. The ROCK Inhibitor Y-27632 Improves Recovery of Human Embryonic Stem Cells after Fluorescence-Activated Cell Sorting with Multiple Cell Surface Markers
11
PubMed Central. Suspension culture improves iPSC expansion and pluripotency phenotype
12
Cell Stem Cell. Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency
13
Nature Communications. Parallel derivation of isogenic human primed and naive induced pluripotent stem cells
14
PubMed Central. Glycolytic Metabolism Plays a Functional Role in Regulating Human Pluripotent Stem Cell State
15
Nature Communications. Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells
16
PubMed. Expansion of 3D human induced pluripotent stem cell aggregates in bioreactors: Bioprocess intensification and scaling-up approaches
17
PubMed Central. Exploring cost reduction strategies for serum free media development
18
Cytotherapy. Good Manufacturing Practice-compliant human induced pluripotent stem cells: from bench to putative clinical products
19
Nature Communications. Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control